A Response to Research Article "Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains" [Letter]
- PMID: 36277246
- PMCID: PMC9584780
- DOI: 10.2147/IDR.S393500
A Response to Research Article "Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains" [Letter]
Conflict of interest statement
The authors report no conflicts of interest in this communication.
Similar articles
-
Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains.Infect Drug Resist. 2022 Oct 10;15:5867-5878. doi: 10.2147/IDR.S382142. eCollection 2022. Infect Drug Resist. 2022. PMID: 36237294 Free PMC article.
-
Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.Pediatr Int. 2019 Jun;61(6):572-577. doi: 10.1111/ped.13847. Epub 2019 Jun 11. Pediatr Int. 2019. PMID: 30908807
-
[Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].Zhonghua Yi Xue Za Zhi. 2002 Nov 10;82(21):1476-9. Zhonghua Yi Xue Za Zhi. 2002. PMID: 12509910 Chinese.
-
[Evaluation of Antibiotics for the Treatment of Bacteremia Due to Extended-spectrum β-Lactamase-producing Escherichia coli].Yakugaku Zasshi. 2015;135(6):829-33. doi: 10.1248/yakushi.14-00253. Yakugaku Zasshi. 2015. PMID: 26028418 Japanese.
-
Extended-spectrum beta-lactamase-producing strains among diarrhoeagenic Escherichia coli-prospective traveller study with literature review.J Travel Med. 2022 Jan 17;29(1):taab042. doi: 10.1093/jtm/taab042. J Travel Med. 2022. PMID: 33834207 Free PMC article. Review.
Cited by
-
Extended spectrum beta lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae in Indonesia and South East Asian countries: GLASS Data 2018.AIMS Microbiol. 2023 Mar 17;9(2):218-227. doi: 10.3934/microbiol.2023013. eCollection 2023. AIMS Microbiol. 2023. PMID: 37091820 Free PMC article.
References
-
- Takemura W, Tashiro S, Hayashi M, et al. Cefmetazole as an alternative to carbapenems against extended-spectrum beta-lactamase-producing Escherichia coli infections based on in vitro and in vivo pharmacokinetics/pharmacodynamics experiments. Pharm Res. 2021;38(11):1839–1846. doi:10.1007/s11095-021-03140-7 - DOI - PubMed
-
- Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR- P. aeruginosa). Clin Infect Dis. 2021;72:1109–1116. doi:10.1093/cid/ciab295 - DOI - PubMed
LinkOut - more resources
Full Text Sources